Sotillo-Piñeiro Elena, Sierrasesúmaga Luis, Patiñno-García Ana
Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA 19140, USA.
Pediatr Res. 2004 Feb;55(2):231-5. doi: 10.1203/01.PDR.0000102455.36737.3C. Epub 2003 Nov 19.
The presence of telomerase activity has been analyzed in almost all tumor types and tumor-derived cell lines. However, there are very few studies that focus on the presence of telomerase activity in bone tumors, and most of them report analysis on very few samples or bone-derived cell lines. The objective of this study was to analyze the telomere length and telomerase activity in primary tumors and metastatic lesions from pediatric osteosarcoma and Ewing's sarcoma patients. The presence of telomerase activity was analyzed by the telomeric repeat amplification protocol assay, and the telomere length was measured by Southern blot. Results were related to survival and clinical outcome. Telomerase activity was detected in 85% of the bone tumor metastases (100% Ewing's sarcomas and 75% osteosarcomas) but only in 12% of the primary tumors (11.1% osteosarcomas and 12.5% Ewing's sarcomas). Bone tumor tissues with telomerase activity had mean telomere lengths 3 kb shorter than those with no detectable telomerase activity (p = 0.041). The presence of telomerase activity was associated with survival (p = 0.009), and longer event-free survival periods were found in patients who lacked telomerase activity compared with those who had detectable telomerase activity levels in their tumor tissues (p = 0.037). The presence of longer telomeres in primary pediatric bone tumors than in metastases could be indicative of alternative mechanisms of lengthening of telomeres for their telomere maintenance rather than telomerase activity. Nevertheless, the activation of telomerase seems to be a crucial step in the malignant progression and acquisition of invasive capability of bone tumors.
几乎在所有肿瘤类型和肿瘤衍生细胞系中都分析了端粒酶活性的存在情况。然而,很少有研究聚焦于骨肿瘤中端粒酶活性的存在情况,并且其中大多数研究报告所分析的样本或骨衍生细胞系数量极少。本研究的目的是分析小儿骨肉瘤和尤因肉瘤患者原发性肿瘤及转移病灶中的端粒长度和端粒酶活性。通过端粒重复序列扩增法检测端粒酶活性的存在情况,并用Southern印迹法测量端粒长度。结果与生存率和临床结局相关。在85%的骨肿瘤转移灶中检测到端粒酶活性(尤因肉瘤为100%,骨肉瘤为75%),但仅在12%的原发性肿瘤中检测到(骨肉瘤为11.1%,尤因肉瘤为12.5%)。具有端粒酶活性的骨肿瘤组织的平均端粒长度比未检测到端粒酶活性的组织短3 kb(p = 0.041)。端粒酶活性的存在与生存率相关(p = 0.009),与肿瘤组织中端粒酶活性可检测的患者相比,肿瘤组织中端粒酶活性未检测到的患者无事件生存期更长(p = 0.037)。小儿原发性骨肿瘤中的端粒比转移灶中的端粒长,这可能表明存在替代的端粒延长机制来维持端粒,而非端粒酶活性。然而,端粒酶的激活似乎是骨肿瘤恶性进展和获得侵袭能力的关键步骤。